Bortenat 2mg, containing the active ingredient bortezomib, is a medication used primarily in the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib functions as a proteasome inhibitor, targeting and inhibiting the 26S proteasome, a cellular complex responsible for degrading proteins. By disrupting this process, bortezomib interferes with the regulatory mechanisms that control cell growth and survival in cancer cells. This inhibition leads to the accumulation of unwanted proteins within the cancer cells, triggering apoptosis (programmed cell death) and ultimately reducing the proliferation of malignant cells. Additionally, bortezomib may affect the tumor microenvironment, making it less conducive to cancer cell survival and growth. Bortenat 2mg injection is typically administered under medical supervision and plays a crucial role in the therapeutic regimen for patients with these specific types of cancer.